Call for Abstract

6th International Conference on Vascular Dementia, will be organized around the theme “Exploring the challenges concerning excellence in dementia research and care”

Vascular Dementia 2017 is comprised of 12 tracks and 91 sessions designed to offer comprehensive sessions that address current issues in Vascular Dementia 2017.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Dementia is a general term for a decline in mental ability severe enough to interfere with daily life. Memory loss is an example. Alzheimer's is the most common type of dementia.

  • Track 1-1Dementia pathophysiology
  • Track 1-2Stroke-related dementia
  • Track 1-3Post stroke dementia
  • Track 1-4Mixed dementia
  • Track 1-5Multi-infarct dementia
  • Track 1-6Sleep and dementia
  • Track 1-7Young onset dementia
  • Track 1-8Parkinson dementia
  • Track 1-9Computational and mathematical modelling of dementia
  • Track 1-10Research on social interventions in dementia
  • Track 1-11Research on non pharmacological interventions in dementia
  • Track 1-12Reiki and Dementia

Dementia is caused by damage to brain cells. This damage interferes with the ability of brain cells to communicate with each other. When brain cells cannot communicate normally, thinking, behavior and feelings can be affected.

  • Track 2-1Epidemiology and prevalence
  • Track 2-2Amyloid protein: A protein of great concern
  • Track 2-3Neurological changes in brain
  • Track 2-4Diabetes induced dementia
  • Track 2-5Neurological changes in brain
  • Track 2-6Genetic associations and susceptibility genes
  • Track 2-7Role of apolipoprotein E
  • Track 2-8Histone modification, DNA methylation

Vascular dementia is defined as inadequate blood flow can damage and eventually kill cells anywhere in the body. In vascular dementia, changes in thinking skills sometimes occur suddenly following strokes that block major brain blood vessels. Vascular brain changes often coexist with changes linked to other types of dementia, including Alzheimer's disease and dementia with Lewy bodies. Vascular dementia symptoms may be most obvious when they happen soon after a major stroke includes confusion, disorientation, trouble speaking or understanding speech and vision loss.

  • Track 3-1Vascular dementia prognosis
  • Track 3-2Senile dementia
  • Track 3-3Senelity
  • Track 3-4Cognitive impairment
  • Track 3-5Advances in vascular dementia cognitive impairment treatment

Almost 40 per cent of people over the age of 65 experience some form of memory loss. When there is no underlying medical condition causing this memory loss, it is known as "age-associated memory impairment," which is considered a part of the normal aging process.

  • Track 4-1Brain ageing and dementia
  • Track 4-2Risk factors of cognitive decline
  • Track 4-3Normal ageing and dementia
  • Track 4-4Neuro-anatomical changes in ageing
  • Track 4-5Functional imaging test
  • Track 4-6Advances of research in ageing and dementia

A range of tests and diagnostic procedures is needed to diagnose dementia, but there are several that are fairly commonly used to diagnose dementia. These tests for dementia are mainly tests of mental abilities, blood tests and brain scans. Tests can help the doctor learn whether dementia is caused by a treatable condition. Even for those dementias that cannot be reversed, knowing the type of dementia a person has can help the doctor prescribe medicines or other treatments that may improve mood and behavior and help the family.

  • Track 5-1Diagnosis of vascular dementia
  • Track 5-2Vascular dementia test
  • Track 5-3Neuroimaging
  • Track 5-4Biomarkers
  • Track 5-5Amyloid and tau imaging
  • Track 5-6Diffusion kurtosis imaging
  • Track 5-7Radiology
  • Track 5-8Hippocampal diffusion tensor imaging
  • Track 5-9Positron emission tomography
  • Track 5-10EEG and brain mapping
  • Track 5-11Role of neurosonsology

Progressive dementia, which is dementia that gets worse with time, is the most common type. Five stages of progressive dementia have been outlined. They are part of the Clinical Dementia Rating (CDR), which professionals use to evaluate the progression of symptoms in patients with dementia. The five stages describe a patient’s ability to perform in six different areas of cognition and functioning: orientation, memory, judgment, home and hobbies, personal care, and community. The stages include early dementia, Moderate dementia, Advanced dementia, Test of dementia stages, Advances in research of dementia stages.

  • Track 6-1Early dementia
  • Track 6-2Moderate dementia
  • Track 6-3Advanced dementia
  • Track 6-4Test of dementia stages
  • Track 6-5Advances in research of dementia stages

Alzheimer's disease and other types of dementia can be a challenging journey, not only for the person diagnosed but also for their family members and loved ones. Caring for someone with Alzheimer's or dementia can seem overwhelming at times, but the more information and support you have, the better you can navigate the demanding road ahead and determine the long-term care options that are best suited to you and your loved one.

There are some Alzheimer’s care preparations that are best done sooner rather than later. It may be hard to consider these questions at first, as it means thinking about a time when your loved one is already well down the road of his or her Alzheimer’s journey.

  • Track 7-1Pediatric dementia
  • Track 7-2Nutritional factors and dementia
  • Track 7-3Malnutrition, undernutrition and obesity in dementia
  • Track 7-4Palliative care in vascular dementia
  • Track 7-5Natural remedies for the treatment
  • Track 7-6Advanced researches for dementia care
  • Track 7-7Advances in neuropharmacology in brain protection and recovery
  • Track 7-8Role of dietry nitrates
  • Track 7-9Admiral Nursing
  • Track 7-10Antipsychotic medications
  • Track 7-11Advance Care Planning
  • Track 7-12End of life care and grief in dementia
  • Track 7-13Picture and Dementia
  • Track 7-14Art and Dementia

Nursing is the protection, promotion, and optimization of health and abilities, prevention of illness and injury, facilitation of healing, alleviation of suffering through the diagnosis and treatment of human response, and advocacy in the care of individuals, families, groups, communities, and populations.

  • Track 8-1Primary mental health care and nursing
  • Track 8-2Assessment and evaluation of mental health
  • Track 8-3Cognitive behavioral therapy and family therapy in nursing
  • Track 8-4Stress and emotional treatment studies and outcomes

The mainstay of management of vascular dementia is the prevention of new strokes. This includes administering antiplatelet drugs and controlling major vascular risk factors. Neuroprotective drugs such as nimodipine, propentofylline, and posatirelin are currently under study and may be useful for vascular dementia. Omentum in the treatment of vascular dementia.

The sub tracks includes Cholinisterase inhibitors, Impact of treatment with N-Acetylcysteine, Oral redox polymer therapeutics, Snoezellen and Multi sensory stimulation, Effect of thioctic and enantiomers, Role of phospholipids, Effects of brain afobazole.

  • Track 9-1Omentum in the treatment of vascular dementia
  • Track 9-2Cholinisterase inhibitors
  • Track 9-3Impact of treatment with N-Acetylcysteine
  • Track 9-4Oral redox polymer therapeutics
  • Track 9-5Snoezellen and Multi sensory stimulation
  • Track 9-6Effect of thioctic and enantiomers
  • Track 9-7Role of phospholipids
  • Track 9-8Effects of brain afobazole

National Plan to Address Alzheimer’s Disease, a national effort to expand research in Alzheimer’s and related dementias prevention and treatment and to move the most promising drugs from discovery into clinical trials.

The Plan aims to prevent and effectively treat Alzheimer’s and related dementias by 2025. Its foundation is the 2011 National Alzheimer’s Project Act (NAPA), which was developed to create and maintain a national strategy to overcome the disease.

  • Track 10-1Future development of therapies
  • Track 10-2Aerobic exercise program
  • Track 10-3Research in induced pluripotent stem cells
  • Track 10-4Researches in amyloid and tau proteins
  • Track 10-5Digital engagement for people with dementia

Brain is an intangible conundrum which buries millions and millions of memories.

Entrepreneurship is the process of designing a new business, i.e. a startup company offering a product, process or service.

We are convinced that these new approaches to entrepreneurship research will have high impact and will lead to some of the most exciting and best publications in the years to come.

Bringing these new approaches together in one track will provide a forum for some of the best scholars in the field to join Vascular Dementia Conference 2017 and it will provide the audience with a look into the future of entrepreneurship research.

  • Track 11-1Simulation semantics
  • Track 11-2Cognitive science
  • Track 11-3Computational theory of mind
  • Track 11-4Next generation of entrepreneurs in neuroscience
  • Track 11-5Neuroscience and brain game
  • Track 11-6Neuromanagement
  • Track 11-7Neuro-industrial-engineering

Animal models for Alzheimer’s disease it is important to think about the human phenotype and what is being modeled in terms of the animal phenotype. The moderator, Bradley Hyman, professor of neurology at Harvard Medical School, said that animal models of Alzheimer’s disease, based on the genetics of the disease and the closely related front temporal dementia, replicate at least some of the pathology. Researchers have been successful at modeling very specific aspects of Alzheimer’s disease in the mouse (e.g., plaques, tangles).

Although these are incomplete models of the human disease, they have been well received in the field as potentially relevant models for use in drug discovery.

  • Track 12-1Protein-protein interactions
  • Track 12-2Primate models
  • Track 12-3Pharmacological and lesion models
  • Track 12-4Transgenic models
  • Track 12-5Genetics of translational models
  • Track 12-6Ethical issues with animal models